Home/Pipeline/COHEALYX®

COHEALYX®

Partial-Thickness Burns

ApprovedCommercial

Key Facts

Indication
Partial-Thickness Burns
Phase
Approved
Status
Commercial
Company

About AVITA Medical

AVITA Medical is a commercial-stage regenerative medicine company focused on transforming acute wound care through its proprietary autologous cell harvesting technology. Its FDA-approved RECELL System is the cornerstone of a platform designed to harness a patient's own skin for healing, with applications expanding beyond burns into traumatic and surgical wounds. The company is actively advancing its pipeline through clinical trials, supported by a commercial infrastructure in the U.S. and international approvals, aiming to improve clinical outcomes and reduce healthcare costs. AVITA's strategy centers on leveraging its core technology across multiple indications while commercializing a portfolio of advanced wound care products.

View full company profile

About AVITA Medical

AVITA Medical is a commercial-stage regenerative medicine company focused on transforming acute wound care through its proprietary autologous cell harvesting technology. Its FDA-approved RECELL System is the cornerstone of a platform designed to harness a patient's own skin for healing, with applications expanding beyond burns into traumatic and surgical wounds. The company is actively advancing its pipeline through clinical trials, supported by a commercial infrastructure in the U.S. and international approvals, aiming to improve clinical outcomes and reduce healthcare costs. AVITA's strategy centers on leveraging its core technology across multiple indications while commercializing a portfolio of advanced wound care products.

View full company profile

About AVITA Medical

AVITA Medical is a commercial-stage regenerative medicine company focused on transforming acute wound care through its proprietary autologous cell harvesting technology. Its FDA-approved RECELL System is the cornerstone of a platform designed to harness a patient's own skin for healing, with applications expanding beyond burns into traumatic and surgical wounds. The company is actively advancing its pipeline through clinical trials, supported by a commercial infrastructure in the U.S. and international approvals, aiming to improve clinical outcomes and reduce healthcare costs. AVITA's strategy centers on leveraging its core technology across multiple indications while commercializing a portfolio of advanced wound care products.

View full company profile

Other Partial-Thickness Burns Drugs

DrugCompanyPhase
PERMEADERM®AVITA MedicalApproved